In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TransVascular Inc.

Division of Medtronic PLC
www.transvascular.com

Latest From TransVascular Inc.

Obesity Intervention: A New Era Of Discovery And Innovation

Device manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease.

Medical Device

Obesity Intervention: A New Era Of Discovery And Innovation

Driven by a vast and underserved market in dire need of safer, less-invasive, more effective solutions, manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease. Indeed the obesity intervention paradigm is rapidly changing as ongoing research provides new insights into the underlying mechanisms behind obesity and bariatric surgery, heralding a new era where the primary treatment target for bariatric surgery is becoming disease specific, rather than targeted at obesity alone.

Medical Device Europe

Medtronic: Making Convergence Pay

Medtronic has been a pioneer in drug/device convergence: creating products whose therapeutic benefit stems equally from the features of their drug and device components. Convergence represents one of the medical device industry's most promising opportunities. But getting past the cultural differences between medical device and biotech companies can be huge.
BioPharmaceutical Medical Device

Cardio3: Moving from Science Project to Business Model in Stem Cells

Cardiac stem cell therapy for regenerating diseased heart tissue has been long on promise but short on delivery. A Belgian incubator and start-up hope to finally bring this treatment to market.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Medtronic PLC
  • Senior Management
  • Norwick Goodspeed, Pres. & CEO
    Joshua Makower, MD, Chmn. & CTO
  • Contact Info
  • TransVascular Inc.
    Phone: (650) 473-4500
    1505-D Adams Dr.
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register